Chris Bryant MP: speeches

Chris Bryant MP: full overview

4 Jul 2024–3 Jul 2025

How these years work

Our reporting years run from 4 July to 3 July, starting with the 2024 general election. They are not official parliamentary sessions. Office costs keep IPSA’s April–March financial years. Records may cover only part of a year; a missing record does not mean no work was done.

Compare reporting years, sessions and IPSA financial years.

Parliamentary contributions: dates and coverage

Source checked
19 Nov 2026
Last successful import
19 Nov 2026
Records dated through
18 Nov 2026
Selected period
Reporting year 1: 4 Jul 2024 to 3 Jul 2025
Completeness
Published snapshot: 20,988 records in the source window 21 Aug 2026 to 19 Nov 2026. The published snapshot covers its stated source window. Older imports can extend beyond it; not every public speech is included.

How to read these datesOfficial source

This page lists the parliamentary spoken contributions we hold for Chris Bryant in the reporting year 1 (4 Jul 2024 to 3 Jul 2025). It does not include every public speech, party-conference address or constituency event. Latest retained contribution in this period: 2 Jul 2025. The source check date and dataset limits are shown above. Open the Hansard link for the full debate and surrounding context.

Clear speech filters

Read what this MP said, asked and contributed in Parliament.

676 published records · newest first.

Speeches

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    There are all sorts of bids coming in now, none of which I am in charge of, but we have seen significant added investments in the UK since the autumn. For instance, Iberdrola is doubling its investment through Scottish Power from £12 billion to £24 billion over the next four years, and Blackstone has confirmed a £10 billion investment in Blyth in Northumberland.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    Yes, and I agree with everything my hon. Friend says. The Oxford-Cambridge corridor is really important. Reading the newspapers over the weekend, I was intrigued by how many Conservative commentators kept on saying, “What I don’t understand is why the Conservatives didn’t do this over the last 14 years.”

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    I am afraid that I will have to write to the hon. Lady on that last question, as I am not sure precisely where we are with an impact assessment. She is absolutely right that the UK’s life sciences sector generated something like £108 billion in turnover in the financial year ending 2022—a sharp 13% increase on the previous year. We want to build on that.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    As I have already said, we had £63 billion of investment at the summit before Christmas, and we have had £14 billion of investment since Christmas. I have a specific responsibility for data in the Department for Science, Innovation and Technology, and the number of data centres investing in the UK is significant. We now have 500, which puts us third after the United States of America and Germany. We are determined to grow the economy. The hon.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    Some of what I have already pointed out is really important. We have already said that we will have the lowest corporation tax rate in the G7, at 25%, and we are sticking with that. We have made sure that we are investing in our public services so that people can have a guarantee of proper public services in this country.

  • 3 Feb 2025 · AstraZeneca · Hansard source
    More

    Not necessarily for this specific deal, but certainly for a deal with AstraZeneca, yes.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    Not only have we set aside £520 million precisely to be able to invest in the life sciences industry with an innovation fund, we are very keen to work with specific businesses to understand how they can make more secure, long-term investment. The single most important thing for most people making an investment in the UK is whether they believe there is political, fiscal and financial stability in the UK. That is what we are absolutely determined to deliver.

  • 3 Feb 2025 · AstraZeneca · Hansard source
    More

    No.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    If I might just refer to the first comment first, I am the Member for Rhondda and Ogmore, so I fully understand that investment in one part of the country is obviously great for that part of the country, but it does not necessarily mean that every part of the country is rising with everybody else.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    Regional mayors have an important role to play in helping bring investment into key areas. I am happy to ensure that the meetings that my hon. Friend has asked for take place. This has to be a joint venture between everyone.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    It is good to hear from the Chair of the Select Committee. I want to make it absolutely clear that AstraZeneca is not leaving—people are not losing their jobs because of this decision. There are still 10,000 people employed by AstraZeneca in the UK and, for that matter, it is proceeding with its nasal-based flu vaccine for children, just in a different way. All of that is important. My hon.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    That is the cleverest bid for finance that I have ever heard, so my hon. Friend gets an award for that. She is right that we stand ready at any point to assist key investments of this nature, especially in the life sciences sector. The difference between the amount of money that was theoretically made available by the previous Government and the amount that we were prepared to put forward was remarkably small.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    I would be delighted to meet my hon. Friend knows, as she knows, although I think it would probably be more useful for her if she were to meet Lord Vallance, who is the Minister for life sciences. My hon. Friend is absolutely right; we would of course much prefer this investment to go ahead and to have been able to get this deal over the line.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    I will take support from wherever I can get it, so I am grateful to the right hon. Gentleman. It is a very simple point that when the Government invest in businesses of whatever kind, we have to make sure that we get value for money for the taxpayer, even when there is a very large cheque on the table.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    As the largest company listed on the London Stock Exchange, employing more than 10,000 people and investing about £2.5 billion every year in the UK, AstraZeneca is a close and valued partner to this Government and is critical to the UK’s thriving life sciences sector. We saw that in the covid-19 pandemic, when AstraZeneca partnered with the University of Oxford to create a safe and effective vaccine that was manufactured and distributed around the world, saving millions of lives.

  • 3 Feb 2025 · AstraZeneca · Read the full contribution in Hansard
    More

    The right hon. Lady puts it in a particular way, but it is not a way that is consonant with the facts. The fact is that this deal had not been signed or got over the line by the previous Government, who, as I have said, would quite often announce things and not actually deliver in the end.

  • 3 Feb 2025 · AstraZeneca · Hansard source
    More

    Yes, 100%. I know that my hon. Friend has visited AstraZeneca and spoken to it many times. He is absolutely right to note that there are, I think, 4,000 working at the Macclesfield site, and will continue to do so. I am sure that AstraZeneca has a very strong future in Macclesfield. Nothing in this decision changes that one iota.

  • 3 Feb 2025 · AstraZeneca · Hansard source
    More

    I think the hon. Gentleman needs to speak to the hon. Member who spoke earlier—oh, he’s left. I actually believe that the vaccines saved lives; I do not believe that they lost people their lives. I am afraid that the hon. Gentleman and I will never be united on that front.

  • 3 Feb 2025 · AstraZeneca · Hansard source
    More

    Of course we feel regretful. We would have preferred to get this over the line but that was not possible, in large measure because AstraZeneca decided that it did not add up in whatever particular way for it. The right hon. Gentleman makes one very good point: we want a manufacturing provision in the country, and my colleague Lord Vallance is working on that very closely with the sector.

  • 27 Jan 2025 · Creative Industries · Hansard source
    More

    Stoke-on-Trent? [ Laughter . ]

  • 27 Jan 2025 · Creative Industries · Hansard source
    More

    I have two Liberal Democrats wanting to intervene. It is very difficult to decide between them. I will give way to the one who has not taken part.

  • 27 Jan 2025 · Creative Industries · Read the full contribution in Hansard
    More

    The hon. Lady makes a very good point about the Edinburgh festivals; I hope that the Hansard Reporters heard the “s” at the end. Sometimes people just refer to the Edinburgh international festival, but there is a series of festivals, including book and television festivals. That ecosystem has managed to grow and grow; it is precisely the kind of thing that we want to do. Another element of the Edinburgh international festivals is that there is a cluster there.

  • 27 Jan 2025 · Creative Industries · Hansard source
    More

    I am very tempted to.

  • 27 Jan 2025 · Creative Industries · Read the full contribution in Hansard
    More

    I support securing more licensing, greater control of rights and legal clarity for all. The hon. Gentleman is absolutely right. As I said to the right hon. Member for Maldon, there is not a version of rights reservation that works at the moment and is simple and easy. As an author, I know that if someone wants to register for the public lending right, they have to go online and register each of their works.

  • 27 Jan 2025 · Creative Industries · Hansard source
    More

    indicated dissent .

Explore activity by topic or department

Contributions by debate topic

4 Jul 2024–3 Jul 2025. Existing keyword taxonomy applied to official debate titles and contributions; a contribution may appear in more than one topic and unclassified records are retained.

View as listCommunities and local government: 58Communities and local government58Culture, media and sport: 114Culture, media and sport114Defence and foreign affairs: 18Defence and foreign affairs18Democracy and constitution: 98Democracy and constitution98Economy and business: 188Economy and business188Education and skills: 46Education and skills46Environment and energy: 18Environment and energy18Health and care: 25Health and care25Housing and planning: 5Housing and planning5Immigration and borders: 1Immigration and borders1Justice and policing: 30Justice and policing30Social security and pensions: 11Social security and pensions11Transport: 14Transport14Unclassified: 321Unclassified321
What this shows and doesn't show
4 Jul 2024–3 Jul 2025. Existing keyword taxonomy applied to official debate titles and contributions; a contribution may appear in more than one topic and unclassified records are retained. Published records do not measure effort or effectiveness. Methodology.
Department or topicPublished records
Communities and local government58
Culture, media and sport114
Defence and foreign affairs18
Democracy and constitution98
Economy and business188
Education and skills46
Environment and energy18
Health and care25
Housing and planning5
Immigration and borders1
Justice and policing30
Social security and pensions11
Transport14
Unclassified321

Published records only — not a full account of an MP’s work. How we work →